<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Up to 20% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> have been linked to <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:e sem="disease" ids="C1264606" disease_type="Disease or Syndrome" abbrv="">persistent infections</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, almost <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> contain immune infiltrates, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-associated inflammatory cells play broad roles in different stages of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> development and malignant progression </plain></SENT>
<SENT sid="2" pm="."><plain>Cytokines are important mediators of the inflammatory effect on <z:mp ids='MP_0002006'>tumorigenesis</z:mp> both in <z:mp ids='MP_0001845'>inflammation</z:mp>-induced <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and in the <z:mp ids='MP_0001845'>inflammation</z:mp> that follows <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> development </plain></SENT>
<SENT sid="3" pm="."><plain>We have shown interleukin (IL)-6 to be an important <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> promoter in early <z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (CAC) </plain></SENT>
<SENT sid="4" pm="."><plain>IL-6 is mainly produced by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-infiltrating myeloid cells under the control of NF-ÎºB </plain></SENT>
<SENT sid="5" pm="."><plain>IL-6 promotes proliferation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-initiating cells derived from the intestinal epithelium and protects them from apoptotic elimination </plain></SENT>
<SENT sid="6" pm="."><plain>These pro-survival and proliferative effects of IL-6 are mainly mediated by STAT3, whose ablation in intestinal epithelial cells significantly reduces CAC <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>More recently, we found a critical role for IL-23 and its downstream cytokines IL-17 and IL-22 in the development of CAC </plain></SENT>
<SENT sid="8" pm="."><plain>These findings suggest that such cytokines or the cells that produce them may provide new therapeutic or preventive targets in forms of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> that are linked to <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
</text></document>